What do systematic reviews say?

BM‐MNCs vs mPBSCs

• Autologous cells derived from different sources and administered using different regimens for 'no‐option' critical… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 150 participants
  Low

Lower vs higher cumulative dose dexamethasone regimen

Lower showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with higher cumulative dose dexamethasone regimen (low certainty).

• Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants 2023 · Cochrane Headline outcomes only
  RR 1.03 [0.86, 1.24]
  7 studies · 268 participants
  Low

Lower vs higher cumulative dose dexamethasone regimen

Lower showed no clear difference in death or cerebral palsy at 1 to 3 years compared with higher cumulative dose dexamethasone regimen (low certainty).

• Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants 2023 · Cochrane Headline outcomes only
  RR 1.74 [0.94, 3.24]
  4 studies · 193 participants
  Low

Lower vs higher cumulative dose dexamethasone regimen

It is very uncertain whether lower changes death or abnormal neurodevelopmental outcome (various definitions)… compared with higher cumulative dose dexamethasone regimen (very low certainty).

• Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants 2023 · Cochrane Headline outcomes only
  RR 1.86 [0.98, 3.53]
  3 studies · 100 participants
  Very low

Lower vs higher availability (i.e. fewer versus more options) of food products

• Altering the availability or proximity of food, alcohol, and tobacco products to change their selection and consumption 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 154 participants
  Low

Lower vs higher availability (i.e. fewer versus more options) of food products

• Altering the availability or proximity of food, alcohol, and tobacco products to change their selection and consumption 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 150 participants
  Low

Lower vs higher proximity (i.e. placed farther away versus placed nearer) of food products

• Altering the availability or proximity of food, alcohol, and tobacco products to change their selection and consumption 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 41 participants
  Very low

Lower vs higher proximity (i.e. placed farther away versus placed nearer) of food products

• Altering the availability or proximity of food, alcohol, and tobacco products to change their selection and consumption 2019 · Cochrane Headline outcomes only
  no estimate extracted
  12 studies · 1098 participants
  Low

Higher blood flow vs standard blood flow

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 499 participants
  Low

Higher blood flow vs standard blood flow

The review found no eligible studies for this question.

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Higher blood flow vs standard blood flow

The review found no eligible studies for this question.

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Higher blood flow vs standard blood flow

The review found no eligible studies for this question.

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in overall survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.8 [0.6, 1.08]
  2 studies · 947 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines leads to lower adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (high certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.62 [0.4, 0.97]
  4 studies · 279 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.78 [0.25, 2.46]
  3 studies · 162 participants
  Low

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose delay) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.76 [0.52, 1.12]
  3 studies · 238 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in disease‐free survival ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.84 [0.65, 1.09]
  1 study · 828 participants
  Moderate

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in pathological complete response (no invasive cancer in breast or… compared with anthracyclines followed by taxane (high certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 1.15 [0.96, 1.38]
  4 studies · 1280 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 1.25 [0.86, 1.82]
  1 study · 280 participants
  Moderate